NI201000038A - Nuevas sales de adición de inhibidores de la enzima de conversión de la angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que las contienen. - Google Patents

Nuevas sales de adición de inhibidores de la enzima de conversión de la angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que las contienen.

Info

Publication number
NI201000038A
NI201000038A NI201000038A NI201000038A NI201000038A NI 201000038 A NI201000038 A NI 201000038A NI 201000038 A NI201000038 A NI 201000038A NI 201000038 A NI201000038 A NI 201000038A NI 201000038 A NI201000038 A NI 201000038A
Authority
NI
Nicaragua
Prior art keywords
donoring
inhibitors
acids
pharmaceutical compositions
addition
Prior art date
Application number
NI201000038A
Other languages
English (en)
Inventor
De Nanteuil Guillaume
Portevin Bernard
Gloanec Philippe
Parmentier Jean-Gilles
Benoist Alain
Verbeuren Tony
Rupin Alain
Courchay Christine
Simonet Serge
Original Assignee
Servier Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39539691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NI201000038(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Servier Lab filed Critical Servier Lab
Publication of NI201000038A publication Critical patent/NI201000038A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/52—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C07D233/36—One oxygen atom with hydrocarbon radicals, substituted by nitrogen atoms, attached to ring nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10—Spiro-condensed systems

Abstract

Compuestos de fórmula (I): (A)m.(B)n (I) en la que A respresenta un compuesto inhibidor de la enzima de conversión de la angiotensina que conlleva al menos una función básica salificable, B representa un compuesto que conlleva al menosuna función ácida salificable y al menos un grupo donador de NO, m representa el número de funciones ácidas salificada de B y n representa el número de funciones básica salificadas de A, debiendo entender que el o los enlaces entre A y B son de tipo iónico. Medicamentos.
NI201000038A 2007-09-21 2010-03-19 Nuevas sales de adición de inhibidores de la enzima de conversión de la angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que las contienen. NI201000038A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0706629A FR2921365B1 (fr) 2007-09-21 2007-09-21 Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Publications (1)

Publication Number Publication Date
NI201000038A true NI201000038A (es) 2010-07-15

Family

ID=39539691

Family Applications (1)

Application Number Title Priority Date Filing Date
NI201000038A NI201000038A (es) 2007-09-21 2010-03-19 Nuevas sales de adición de inhibidores de la enzima de conversión de la angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que las contienen.

Country Status (43)

Country Link
US (1) US7981920B2 (es)
EP (2) EP2236495A1 (es)
JP (1) JP4903187B2 (es)
KR (1) KR101070056B1 (es)
CN (1) CN101391973A (es)
AP (1) AP2010005204A0 (es)
AR (1) AR068488A1 (es)
AT (1) ATE476416T1 (es)
AU (1) AU2008217013B8 (es)
BR (1) BRPI0804073A2 (es)
CA (1) CA2639700C (es)
CL (1) CL2008002725A1 (es)
CR (1) CR11320A (es)
CY (1) CY1110782T1 (es)
DE (1) DE602008002027D1 (es)
DK (1) DK2039682T3 (es)
EA (1) EA015092B1 (es)
EC (1) ECSP10010040A (es)
ES (1) ES2349493T3 (es)
FR (1) FR2921365B1 (es)
GE (1) GEP20125479B (es)
HN (1) HN2010000533A (es)
HR (1) HRP20100545T1 (es)
JO (1) JO2664B1 (es)
MA (1) MA30320B1 (es)
MX (1) MX2008011954A (es)
MY (1) MY144927A (es)
NI (1) NI201000038A (es)
NZ (1) NZ572988A (es)
PA (1) PA8796701A1 (es)
PE (1) PE20091190A1 (es)
PL (1) PL2039682T3 (es)
PT (1) PT2039682E (es)
RS (1) RS51433B (es)
SA (1) SA08290599B1 (es)
SG (1) SG151200A1 (es)
SI (1) SI2039682T1 (es)
SV (1) SV2010003511A (es)
TN (1) TN2010000111A1 (es)
TW (1) TWI370118B (es)
UY (1) UY31339A1 (es)
WO (1) WO2009074733A2 (es)
ZA (1) ZA200808062B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2961105B1 (fr) 2010-06-15 2013-02-08 Servier Lab Utilisation de l'association d'un inhibiteur du courant if sinusal et d'un inhibiteur de l'enzyme de conversion de l'angiotensine pour le traitement de l'insuffisance cardiaque
US10314816B2 (en) 2012-06-08 2019-06-11 Wisconsin Alumni Research Foundation Antimicrobial compounds, compositions and methods of use thereof
CN103848795B (zh) * 2014-03-07 2016-08-17 山东大学 一种1,2,5-噁二唑-2-氧化物组蛋白去乙酰化酶抑制剂及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4218582A1 (de) * 1992-06-05 1993-12-09 Cassella Ag Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
IT1295694B1 (it) * 1996-11-14 1999-05-27 Nicox Sa Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
AU5403499A (en) * 1998-08-26 2000-03-21 Queen's University At Kingston Methods for remodeling neuronal and cardiovascular pathways
DE10033580A1 (de) 2000-04-10 2001-10-11 Bayer Ag Verfahren zur Herstellung von Ditaurin und seinen Salzen
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
WO2004050084A2 (en) * 2002-11-29 2004-06-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ace-inhibitors having antioxidant and nitricoxid-donor activity
US20070010571A1 (en) * 2003-08-20 2007-01-11 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2006206249A1 (en) * 2005-01-21 2006-07-27 Nicox S.A. Cardiovascular compounds comprising heterocyclic nitric oxide donor group compositions and methods of use
US20080293678A1 (en) * 2005-03-18 2008-11-27 Nitromed, Inc. Organic Nitric Oxide Donor Salts of Angiotensin Converting Enzyme Inhibitors, Compositions and Methods of Use
RU2271202C1 (ru) * 2005-05-04 2006-03-10 Михаил Владимирович Покровский Способ коррекции эндотелиальной дисфункции
WO2007016136A2 (en) * 2005-07-28 2007-02-08 Nitromed, Inc. Organic nitric oxide enhancing salts of cyclooxygenase-2 selective inhibitors, compositons and methods of use
US7838023B2 (en) * 2005-11-16 2010-11-23 Nitromed, Inc. Furoxan compounds, compositions and methods of use
WO2007060112A1 (en) * 2005-11-23 2007-05-31 Nicox S.A. Salicylic acid derivatives

Also Published As

Publication number Publication date
EA015092B1 (ru) 2011-06-30
AU2008217013A1 (en) 2009-04-09
BRPI0804073A2 (pt) 2009-06-16
WO2009074733A2 (fr) 2009-06-18
US7981920B2 (en) 2011-07-19
GEP20125479B (en) 2012-04-25
SI2039682T1 (sl) 2010-10-29
KR101070056B1 (ko) 2011-10-04
ATE476416T1 (de) 2010-08-15
AP2010005204A0 (en) 2010-04-30
JP2009137935A (ja) 2009-06-25
PT2039682E (pt) 2010-09-27
KR20090031298A (ko) 2009-03-25
MX2008011954A (es) 2009-03-20
EP2039682A1 (fr) 2009-03-25
CA2639700C (fr) 2012-08-28
PE20091190A1 (es) 2009-08-09
CL2008002725A1 (es) 2009-06-12
PL2039682T3 (pl) 2010-10-29
CR11320A (es) 2010-06-29
TW200920352A (en) 2009-05-16
CA2639700A1 (fr) 2009-03-21
PA8796701A1 (es) 2009-09-17
FR2921365A1 (fr) 2009-03-27
AU2008217013A8 (en) 2012-10-04
EA200801863A1 (ru) 2009-04-28
AU2008217013B8 (en) 2012-10-04
TN2010000111A1 (fr) 2011-09-26
SV2010003511A (es) 2010-07-29
ES2349493T3 (es) 2011-01-04
EP2039682B1 (fr) 2010-08-04
CY1110782T1 (el) 2015-06-10
SA08290599B1 (ar) 2011-05-04
EP2236495A1 (fr) 2010-10-06
CN101391973A (zh) 2009-03-25
HN2010000533A (es) 2013-07-08
MY144927A (en) 2011-11-30
JO2664B1 (en) 2012-06-17
JP4903187B2 (ja) 2012-03-28
US20090082393A1 (en) 2009-03-26
AU2008217013B2 (en) 2012-08-16
WO2009074733A3 (fr) 2009-08-20
ECSP10010040A (es) 2010-04-30
ZA200808062B (en) 2009-11-25
AR068488A1 (es) 2009-11-18
SG151200A1 (en) 2009-04-30
UY31339A1 (es) 2008-10-31
DK2039682T3 (da) 2010-11-08
TWI370118B (en) 2012-08-11
NZ572988A (en) 2010-07-30
HRP20100545T1 (hr) 2010-11-30
RS51433B (en) 2011-04-30
MA30320B1 (fr) 2009-04-01
FR2921365B1 (fr) 2012-10-12
DE602008002027D1 (de) 2010-09-16

Similar Documents

Publication Publication Date Title
CY1125155T1 (el) Κρυσταλλικες μορφες αναστολεα προλυλο υδροξυλασης
CR11252A (es) Nuevos derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met
UY31260A1 (es) Compuestos de pirazol, composiciones conteniendolos y aplicaciones.
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CO6331463A2 (es) Nuevos derivados de triazolo(4,3-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CO6331467A2 (es) Nuevos derivados de imidazo(1,2-a)piridina, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion particularmente como inhibidores de met
CR20140412A (es) Inhibidores de la metalproteinasa matriz
CR10206A (es) Acidos4-fenil-tiazol-5-carboxilicos amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
NI201000038A (es) Nuevas sales de adición de inhibidores de la enzima de conversión de la angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que las contienen.
AR054113A1 (es) Forma cristalina solida de pantoprazol como acido libre, sales derivadas del mismo y proceso para su preparacion
AR061740A1 (es) Nuevos derivados naftalenicos, su procedimiento de praparacion y las composiciones farmaceuticas que los contienen
CU20100051A7 (es) Nuevas sales de adición de inhibidores de la enzima de conversión de angiotensina a ácidos donadores de no, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CO6321154A2 (es) Nuevas sales de adicion de inhibidores de la enzima de conversion de la angiotensina acidos donadores de no, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen
GT201000184A (es) Nuevos derivados de ácido 2-mercaptociclopentanocarboxílico, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20130037A7 (es) Nuevos derivados dihidrobenzoxatiazepinas, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
NI200900114A (es) Nuevos derivados de azabiciclicos su procedimiento de preparación y las composiciones farmacéuticas que los contienen.
CO6400222A2 (es) Derivados de 6-(6-o-cicloalquil o de 6-nh-cicloalquil-triazolopiridazina-sulfanil) benzotiazoles y bencimidazoles:preparación, aplicación como medicamentos y utilización como inhibidores de la met
HN2010000295A (es) Nuevos derivados de 6- triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion , su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met
NI201200099A (es) Nuevos derivados de azabiciclo [ 3.1.0] hex - 2 - ilo, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
CU20090105A7 (es) Nuevos derivados azabicíclicos, su procedimiento de preparación y las composiciones farmacéuticas que los contienen
SV2010003746A (es) Nuevos derivados de azabiciclo[3.2.0]hept-3-ilo, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
UY31226A1 (es) Nuevos polimorfos de los compuestos 2-{2-cloro-5-{[2s-3-(5-cloro-1??h, 3h-espiro[1,benzofurano-2,4??piperidina]-1??yi)-2-hidroxipropilo]oxi}-4-[(aminometilico)fenoxicarbonilo}-2-acido metilpropanoico, y sus sales clorhidrato e hidroxido de sodio, y c